Source:http://linkedlifedata.com/resource/pubmed/id/19120715
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2009-1-5
|
| pubmed:abstractText |
Hypertensive patients with the cardiometabolic syndrome (CMS) are at increased risk for type 2 diabetes and cardiovascular disease. The authors examined effects of valsartan and hydrochlorothiazide (HCTZ) combined and alone on insulin sensitivity (using homeostasis model assessment-insulin resistance [HOMA-IR]), and inflammatory/metabolic biomarkers in prediabetic hypertensive persons with CMS. Eligible patients entered 16-week therapy with valsartan 320 mg/d (n=189), HCTZ 25 mg/d (n=190), or valsartan/HCTZ 320/25 mg/d (n=187). At the end point, there were no statistically significant differences in HOMA-IR among the 3 groups. HCTZ significantly increased hemoglobin A(1c) and triglyceride concentrations and lowered serum potassium levels vs valsartan. HCTZ also increased plasma aldosterone and C-reactive protein levels. Blood pressure reduction and blood pressure control rates were highest with valsartan/HCTZ. There were no differences between combination valsartan/HCTZ or monotherapies on a measure of insulin sensitivity; however, the negative metabolic effects of HCTZ (increase in triglyceride and hemoglobin A(1c) values) were absent with valsartan/HCTZ, indicating an ameliorating effect of valsartan on these measures.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II Type 1 Receptor...,
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Diuretics,
http://linkedlifedata.com/resource/pubmed/chemical/Hydrochlorothiazide,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Valine,
http://linkedlifedata.com/resource/pubmed/chemical/valsartan
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1524-6175
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
894-903
|
| pubmed:meshHeading |
pubmed-meshheading:19120715-Adolescent,
pubmed-meshheading:19120715-Adult,
pubmed-meshheading:19120715-Aged,
pubmed-meshheading:19120715-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:19120715-Antihypertensive Agents,
pubmed-meshheading:19120715-Diabetes Mellitus, Type 2,
pubmed-meshheading:19120715-Diuretics,
pubmed-meshheading:19120715-Double-Blind Method,
pubmed-meshheading:19120715-Drug Therapy, Combination,
pubmed-meshheading:19120715-Female,
pubmed-meshheading:19120715-Humans,
pubmed-meshheading:19120715-Hydrochlorothiazide,
pubmed-meshheading:19120715-Hypertension,
pubmed-meshheading:19120715-Male,
pubmed-meshheading:19120715-Metabolic Syndrome X,
pubmed-meshheading:19120715-Middle Aged,
pubmed-meshheading:19120715-Prediabetic State,
pubmed-meshheading:19120715-Risk Factors,
pubmed-meshheading:19120715-Tetrazoles,
pubmed-meshheading:19120715-Valine,
pubmed-meshheading:19120715-Young Adult
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome.
|
| pubmed:affiliation |
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. dion.zappe@novartis.com
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|